Barry Bonds TRT: How a Regular Patient Would Get Access to Testosterone Replacement Therapy

What the Barry Bonds Case Actually Tells Us About Testosterone

The BALCO investigation, which ran from 2002 through Bonds's 2011 perjury conviction (later vacated), introduced millions of people to terms like "the cream" and "the clear." Those substances were later identified by federal prosecutors as testosterone-based and THG-based performance-enhancing compounds. Bonds testified before a grand jury that he used them but said he believed they were flaxseed oil and a recovery balm. A federal appeals court vacated his conviction in 2015.

What "The Cream" Actually Was

Federal court documents and testimony from BALCO founder Victor Conte identified "the cream" as a topical blend of testosterone and epitestosterone. Topical testosterone is chemically identical to the FDA-approved gels prescribed today, including AndroGel 1.62% and Testim. The delivery route, transdermal absorption through skin, is the same mechanism. The difference between illicit sport use and legitimate medicine is diagnosis, dose, and medical oversight.

Why This Case Matters Clinically

The Bonds case illustrated that exogenous testosterone produces measurable effects on lean body mass and recovery. A 2004 landmark trial published in the New England Journal of Medicine (N=61) showed that testosterone enanthate at supraphysiologic doses (600 mg/week) increased fat-free mass by 6.1 kg over 10 weeks in healthy men without exercise, compared to 3.2 kg in the placebo-plus-exercise group [1]. Athletes chasing that effect were using doses far above anything a TRT clinic would prescribe. Therapeutic TRT targets mid-normal physiologic levels, not supraphysiologic ones.

How Hypogonadism Is Diagnosed: The Clinical Criteria a Patient Must Meet

The Two-Draw Rule

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states that a diagnosis requires two morning fasting serum total testosterone values below 300 ng/dL, drawn on separate days [2]. A single low reading is not sufficient. Labs should be collected between 7 a.m. And 10 a.m. Because testosterone follows a diurnal rhythm that peaks in the early morning. One low reading obtained at 3 p.m. Is not diagnostic.

Symptom Requirements

Lab values alone do not qualify a patient. The Endocrine Society guideline specifies that symptoms must be present. Recognized symptoms include decreased libido, erectile dysfunction, reduced energy, depressed mood, decreased muscle mass, increased body fat, and reduced bone density [2]. A patient with borderline labs and no symptoms is generally not a TRT candidate under current guidelines.

Secondary Testing

After two low testosterone readings, a clinician will typically order luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic dysfunction). Prolactin and thyroid-stimulating hormone (TSH) are often added because both elevated prolactin and thyroid dysfunction can suppress testosterone independently. A 2021 review in JAMA Internal Medicine noted that secondary hypogonadism accounts for roughly 40% of male hypogonadism cases and may be reversible if the underlying cause, such as obesity or obstructive sleep apnea, is treated [3].

The Standard TRT Medications a Prescriber Can Order

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most commonly prescribed forms in the United States. Both are FDA-approved. A typical starting dose for testosterone cypionate is 100 mg intramuscularly every 7 days, or 200 mg every 14 days [4]. Patients who self-administer at home use a 1 to 1.5 inch, 23-gauge needle injected into the lateral thigh or gluteal muscle. Peak serum levels occur 24 to 48 hours post-injection; trough levels fall just before the next dose, which can cause mood fluctuation. Weekly dosing reduces that swing compared to biweekly dosing.

Transdermal Testosterone

AndroGel 1.62% (testosterone gel) is FDA-approved at a starting dose of 40.5 mg applied to the shoulders or upper arms once daily [4]. Gel avoids injection-site discomfort but carries a transfer risk to partners or children through skin contact. Patients must wash hands thoroughly and cover application sites with clothing until the gel dries. Serum levels are more stable day-to-day than with injectables.

Testosterone Pellets

Subcutaneous pellets (Testopel) are implanted in the buttock or flank under local anesthesia every 3 to 6 months. Each pellet delivers approximately 75 mg of testosterone; typical doses range from 450 mg to 900 mg per insertion. Pellets are convenient for patients who cannot self-inject, but dose adjustment mid-cycle is not possible.

Nasal and Buccal Options

Natesto, a nasal testosterone gel dosed at 11 mg three times daily, is FDA-approved and preserves LH pulsatility better than other formulations, making it a consideration for men who want to preserve fertility [4]. Buccal tablets (Striant) are placed against the upper gum twice daily but are rarely prescribed due to local irritation rates reported at roughly 16% in clinical trials [4].

How to Actually Get a TRT Prescription: The Step-by-Step Process

A regular patient, meaning someone who is not a professional athlete and not under federal investigation, goes through the following sequence to access TRT legally.

Step 1: Primary Care or Telehealth Intake

A patient contacts either a primary care physician or an FDA-registered telehealth clinic. During intake, the clinician collects a full symptom history using a validated tool such as the Aging Males' Symptoms (AMS) scale. The AMS scale contains 17 items scored on a 1-to-5 Likert scale; a total score above 37 is considered moderate-to-severe hypogonadism symptom burden and supports further workup [5].

Step 2: Lab Order

The clinician orders a morning serum panel. At minimum this includes total testosterone, LH, FSH, complete blood count (CBC), and a comprehensive metabolic panel (CMP). Many clinicians also add free testosterone, sex hormone-binding globulin (SHBG), PSA (in men over 40), estradiol, and prolactin at baseline. SHBG is worth measuring because it binds testosterone tightly; a patient with high SHBG may have a normal total testosterone but a low free testosterone, and vice versa.

Step 3: Clinician Review and Shared Decision-Making

If both draws confirm total testosterone below 300 ng/dL with matching symptoms, the clinician discusses treatment options. The conversation must include risk disclosure: erythrocytosis (hematocrit elevation), suppression of endogenous LH and FSH with consequent reduction in testicular size and sperm production, potential worsening of untreated sleep apnea, and unknown long-term cardiovascular effects. The TRAVERSE trial (N=5,246, published in NEJM 2023) found no significant difference in major adverse cardiovascular events between testosterone-treated and placebo men with hypogonadism over a median 22 months, though atrial fibrillation was numerically higher in the testosterone arm [6].

Step 4: Prescription and Dispensing

Testosterone is a Schedule III controlled substance under the DEA. A prescriber with a valid DEA number can write a controlled substance prescription. Telehealth prescribers must comply with state-specific telehealth laws; as of 2025, federal rules still require that Schedule III prescriptions from telehealth providers follow the Ryan Haight Act framework. Patients receive the medication at a licensed pharmacy. Most telehealth TRT platforms coordinate dispensing through compounding pharmacies for testosterone cypionate or through retail chains for branded products.

Step 5: Follow-Up Monitoring

The Endocrine Society recommends repeat total testosterone, CBC, and PSA at 3 to 6 months after starting TRT, then annually thereafter [2]. Hematocrit above 54% is an indication to reduce dose or donate blood, as polycythemia increases thrombosis risk. PSA rises of more than 1.4 ng/mL above baseline within the first year warrant urology referral. Estradiol is monitored because aromatase converts testosterone to estradiol; elevated estradiol causes gynecomastia and may blunt TRT benefit. Most clinicians target estradiol between 20 and 40 pg/mL.

The Difference Between Therapeutic TRT and the Doses Alleged in the BALCO Case

This distinction matters because patients often arrive at a clinic having read about athletes using 500 to 1,000 mg of testosterone per week and wonder whether those doses are what they would receive.

They are not. Standard TRT targets a serum total testosterone of 400 to 700 ng/dL, the mid-normal reference range for adult men [2]. Achieving that range typically requires 80 to 150 mg of testosterone cypionate per week. The supraphysiologic doses associated with athletic doping push serum levels to 1,500 ng/dL or higher. At those levels, erythrocytosis, hypertension, dyslipidemia, and hepatotoxicity risks rise substantially [7].

The 2004 NEJM trial cited earlier [1] used 600 mg per week, which is roughly 4 to 6 times a therapeutic dose. Muscle mass gains at therapeutic doses are real but modest. A 2016 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (23 RCTs, N=1,083) found that TRT increased lean mass by a mean of 1.6 kg and reduced fat mass by 1.6 kg compared to placebo over 3 to 12 months [8]. Bonds-era allegations involved doses and combinations no responsible clinician would prescribe.

Human Growth Hormone: What Bonds Was Also Alleged to Have Used

HGH was also named in BALCO testimony. Recombinant human growth hormone (somatropin) is FDA-approved for adult growth hormone deficiency (AGHD), which requires biochemical confirmation via insulin tolerance test or glucagon stimulation test [9]. The diagnosis is rare; estimated prevalence of AGHD is roughly 1 to 3 per 10,000 adults. Off-label use for body composition in non-deficient adults is not FDA-approved.

A 2007 Cochrane review (N=220 across 27 studies) found that HGH administration in healthy older adults increased lean mass and reduced fat mass but did not improve strength or functional capacity and produced frequent adverse effects including carpal tunnel syndrome, edema, and glucose intolerance [10]. The FDA has sent multiple warning letters to compounding pharmacies dispensing HGH for anti-aging purposes outside approved indications. Any clinic offering HGH without a documented deficiency diagnosis and formal pituitary testing is operating outside guideline-based care.

Fertility Preservation During TRT

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. LH and FSH fall, Leydig cells in the testes reduce endogenous testosterone production, and Sertoli cells reduce sperm output. Azoospermia can develop within 3 to 4 months of starting TRT [11].

Men who want to preserve fertility have two main options. First, they can use human chorionic gonadotropin (hCG), which mimics LH and stimulates continued intratesticular testosterone production and spermatogenesis. A common protocol is 500 IU subcutaneously three times per week alongside testosterone [11]. Second, they can use clomiphene citrate (off-label) or enclomiphene, which block estrogen receptors at the hypothalamus and pituitary, raising endogenous LH and FSH. Both options trade some convenience for fertility protection.

Cardiovascular Monitoring: What the Current Evidence Requires

The TRAVERSE trial is currently the most definitive randomized evidence on TRT cardiovascular safety. Published in NEJM in June 2023 (N=5,246, median follow-up 22 months), it found that testosterone replacement in men aged 45 to 80 with hypogonadism and existing or high risk for cardiovascular disease did not increase the rate of major adverse cardiac events (MACE), defined as non-fatal MI, non-fatal stroke, or cardiovascular death, compared to placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [6]. Atrial fibrillation rates were 3.5% in the testosterone group vs. 2.4% in the placebo group, a statistically significant difference.

The American Heart Association has not issued a formal guideline endorsing TRT specifically for cardiovascular prevention, and TRT is not indicated for that purpose. Clinicians are expected to assess baseline cardiovascular risk before prescribing and to monitor hematocrit, blood pressure, and lipid panel during treatment.

Insurance Coverage and Cost Without Insurance

Most commercial insurance plans cover TRT when hypogonadism is documented with two qualifying labs and a clinical diagnosis code (ICD-10 E29.1 for primary testicular failure or E23.0 for hypopituitarism). Generic testosterone cypionate 200 mg/mL costs approximately $30 to $60 per 10 mL vial at retail pharmacies, enough for 10 to 20 weeks at a 100 mg/week dose. Branded gels such as AndroGel run $300 to $500 per month without insurance. Pellet insertion costs $300 to $600 per session out-of-pocket and is rarely covered.

Telehealth TRT memberships typically charge $100 to $200 per month and include clinician visits, lab coordination, and medication. Patients should verify that the platform uses board-certified physicians, employs DEA-registered prescribers in their state, and orders labs through a CLIA-certified laboratory.